Agilon Health director McLoughlin buys $55,084 in stock

Published 13/12/2024, 23:36
Agilon Health director McLoughlin buys $55,084 in stock

Karen McLoughlin, a director at agilon health, inc. (NYSE:AGL), recently acquired 25,000 shares of the company's common stock. The timing is notable as the stock has declined over 82% year-to-date, though it has shown strength with positive returns in the past month. The shares were purchased at a weighted average price of $2.2034, with transactions occurring between $2.175 and $2.215. This acquisition amounts to a total value of $55,084. Following this transaction, McLoughlin holds a total of 73,166 shares, which includes restricted stock units. According to InvestingPro analysis, agilon health appears undervalued at its current market cap of $915 million, with 12 additional exclusive insights available to subscribers, including detailed valuation metrics and financial health indicators.

In other recent news, Agilon Health has experienced several significant developments. Bernstein SocGen Group initiated coverage of the company with a Market Perform rating, while Jefferies and TD Cowen reduced their price targets. JMP Securities downgraded the stock rating following a third-quarter earnings miss. Agilon Health reported a 28% increase in revenue year-over-year, reaching $1.45 billion, but fell short of the projected $1.47 billion. The company also experienced an adjusted EBITDA loss of $96 million.

Additionally, Agilon Health updated indemnification agreements and relocated its headquarters to Westerville, Ohio. Despite financial challenges, the company reported a 37% year-over-year growth in Medicare Advantage membership and raised its full-year membership guidance. However, Agilon Health revised its full-year 2024 adjusted EBITDA guidance downward, indicating potential financial challenges ahead. These are recent developments that investors may wish to consider.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.